



DXRX
The Diagnostic Network

by

Diaceutics
Better Testing, Better Treatment

Discover DXRX Data
NSCLC

Diaceutics DXRX Data:

Diaceutics is an end-to-end provider of data-driven development and commercialization solutions for world-leading pharma and biotech launching precision medicines. Utilizing multiple integrated pipelines of real-world data on our platform DXRX - The Diagnostic Network®, we offer a robust and complete view of the patient journey, for the required disease, biomarker, test, or platform with a focus on precision medicine.

Prevalence

Based on Diaceutics DXRX data there were approximately

475,102

Americans living with lung cancer in 2023

*coverage is 78.7% based on SEER

Incidence

217,038


Patients were newly diagnosed in 2023

*coverage is 91.1% based on SEER

Demographics & Geographies


Gender

% of people diagnosed with NSCLC in 2023




Age

% diagnosed by age group for metastatic NSCLC



Top 5 states with highest diagnosed patients for Metastatic NSCLC

1. FL
2. CA
3. TX
4. NY
5. OH




● **Top 100 NPI's** test **8.1% of total** metastatic NSCLC patients in 2023

Diagnosis and management

Our unique business rules enable detailed patient analysis through a Diagnostic Deductive Pathway (DDP), providing a granular understanding of each patient. Coupled with expert labeling, our precision medicine approach facilitates precise patient categorization by NSCLC stage, distinguishing metastatic from early-stage cancer patients using testing and healthcare data.

Patients split by stage

● Metastatic - 60.6% ● Early - 39.4%



Most Commonly Tested Biomarkers in NSCLC

*shown in order of testing rate (%) for metastatic patients

| Biomarker | Testing Rate (%) |
|-------------|------------------|
| PD-L1 | 74.7% |
| EGFR | 65.3% |
| BRAF | 63% |
| ALK | 62.8% |
| KRAS | 62.2% |
| ROS1 | 59.4% |
| MET | 59.1% |
| NTRK | 57.4% |
| RET Fusions | 57.4% |

Top Diagnosing specialities

1. Hematology & Oncology
2. Anatomic pathology & Clinical Pathology
3. Pulmonary Disease

54.3% of total metastatic NSCLC patients are tested **by top 3 specialities**

Most common testing methods

1. IHC
2. NGS
3. FISH

80% of the metastatic NSCLC testing is concentrated in **top 70 labs**

Contact us to unlock the power of real-world data

The data used in the Diaceutics data fact sheet is derived from Diaceutics DXRX database of de-identified, real-world patient and lab data. The data used in this report represents the latest real-world patient data from January – December 2023.

© 2024 Diaceutics PLC or its affiliates. All rights reserved.

